

# Global Therapeutic Radioligands Supply, Demand and Key Producers, 2023-2029

https://marketpublishers.com/r/G72246201812EN.html

Date: October 2023

Pages: 118

Price: US\$ 4,480.00 (Single User License)

ID: G72246201812EN

# **Abstracts**

The global Therapeutic Radioligands market size is expected to reach \$ 3154.4 million by 2029, rising at a market growth of 16.7% CAGR during the forecast period (2023-2029).

The key drivers of the radioimmunotherapy market is its potential to deliver highly targeted and precise treatment to cancer cells, sparing healthy tissues and reducing side effects compared to traditional radiation therapies. The ability of RIT to offer personalized treatment options based on specific cancer biomarkers further enhances its appeal in the field of precision medicine. However, the radioimmunotherapy market also faces challenges. One major challenge is the high cost associated with the development and production of radiopharmaceuticals, limiting access for some patients and healthcare systems. Additionally, navigating complex regulatory pathways for approval and reimbursement of RIT products can be time-consuming and resourceintensive for pharmaceutical companies. Furthermore, there may be limited awareness and acceptance of RIT among healthcare professionals and patients, leading to slower adoption rates and market penetration. Addressing these challenges requires continued research and investment in RIT technologies to improve efficacy and cost-effectiveness. Collaborations between pharmaceutical companies, research institutions, and healthcare organizations can facilitate knowledge-sharing and streamline the regulatory process.

Therapeutic Radioligands is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.



This report studies the global Therapeutic Radioligands demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Therapeutic Radioligands, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Therapeutic Radioligands that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Therapeutic Radioligands total market, 2018-2029, (USD Million)

Global Therapeutic Radioligands total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Therapeutic Radioligands total market, key domestic companies and share, (USD Million)

Global Therapeutic Radioligands revenue by player and market share 2018-2023, (USD Million)

Global Therapeutic Radioligands total market by Type, CAGR, 2018-2029, (USD Million)

Global Therapeutic Radioligands total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Therapeutic Radioligands market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences and Clarity Pharmaceuticals, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.



Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Therapeutic Radioligands market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Therapeutic Radioligands Market, By Region: **United States** China Europe Japan South Korea **ASEAN** India Rest of World Global Therapeutic Radioligands Market, Segmentation by Type Beta-emitting Targeted Alpha Therapy

Global Therapeutic Radioligands Market, Segmentation by Application

Solid Tumor



# Non Hodgkin Lymphoma

Companies Profiled:	
Bayer	
Novartis	
Lantheus	
Aurobindo Pharma	
Mundipharma	
China Isotope & Radiation	
Curium Pharmaceuticals	
Gilead Sciences	
Clarity Pharmaceuticals	
Curasight	
Nordic Nanovector	
Philogen	
RadioMedix	
Telix Pharmaceuticals	
Orano Med	
Actinium Pharmaceuticals	
Y-mAbs Therapeutics	



#### **Fusion Pharmaceuticals**

# **Key Questions Answered**

- 1. How big is the global Therapeutic Radioligands market?
- 2. What is the demand of the global Therapeutic Radioligands market?
- 3. What is the year over year growth of the global Therapeutic Radioligands market?
- 4. What is the total value of the global Therapeutic Radioligands market?
- 5. Who are the major players in the global Therapeutic Radioligands market?



# **Contents**

#### 1 SUPPLY SUMMARY

- 1.1 Therapeutic Radioligands Introduction
- 1.2 World Therapeutic Radioligands Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Therapeutic Radioligands Total Market by Region (by Headquarter Location)
- 1.3.1 World Therapeutic Radioligands Market Size by Region (2018-2029), (by Headquarter Location)
  - 1.3.2 United States Therapeutic Radioligands Market Size (2018-2029)
  - 1.3.3 China Therapeutic Radioligands Market Size (2018-2029)
  - 1.3.4 Europe Therapeutic Radioligands Market Size (2018-2029)
  - 1.3.5 Japan Therapeutic Radioligands Market Size (2018-2029)
  - 1.3.6 South Korea Therapeutic Radioligands Market Size (2018-2029)
  - 1.3.7 ASEAN Therapeutic Radioligands Market Size (2018-2029)
  - 1.3.8 India Therapeutic Radioligands Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
  - 1.4.1 Therapeutic Radioligands Market Drivers
  - 1.4.2 Factors Affecting Demand
- 1.4.3 Therapeutic Radioligands Major Market Trends

#### 2 DEMAND SUMMARY

- 2.1 World Therapeutic Radioligands Consumption Value (2018-2029)
- 2.2 World Therapeutic Radioligands Consumption Value by Region
  - 2.2.1 World Therapeutic Radioligands Consumption Value by Region (2018-2023)
- 2.2.2 World Therapeutic Radioligands Consumption Value Forecast by Region (2024-2029)
- 2.3 United States Therapeutic Radioligands Consumption Value (2018-2029)
- 2.4 China Therapeutic Radioligands Consumption Value (2018-2029)
- 2.5 Europe Therapeutic Radioligands Consumption Value (2018-2029)
- 2.6 Japan Therapeutic Radioligands Consumption Value (2018-2029)
- 2.7 South Korea Therapeutic Radioligands Consumption Value (2018-2029)
- 2.8 ASEAN Therapeutic Radioligands Consumption Value (2018-2029)
- 2.9 India Therapeutic Radioligands Consumption Value (2018-2029)

#### 3 WORLD THERAPEUTIC RADIOLIGANDS COMPANIES COMPETITIVE ANALYSIS

3.1 World Therapeutic Radioligands Revenue by Player (2018-2023)



- 3.2 Industry Rank and Concentration Rate (CR)
  - 3.2.1 Global Therapeutic Radioligands Industry Rank of Major Players
  - 3.2.2 Global Concentration Ratios (CR4) for Therapeutic Radioligands in 2022
  - 3.2.3 Global Concentration Ratios (CR8) for Therapeutic Radioligands in 2022
- 3.3 Therapeutic Radioligands Company Evaluation Quadrant
- 3.4 Therapeutic Radioligands Market: Overall Company Footprint Analysis
  - 3.4.1 Therapeutic Radioligands Market: Region Footprint
  - 3.4.2 Therapeutic Radioligands Market: Company Product Type Footprint
  - 3.4.3 Therapeutic Radioligands Market: Company Product Application Footprint
- 3.5 Competitive Environment
  - 3.5.1 Historical Structure of the Industry
  - 3.5.2 Barriers of Market Entry
  - 3.5.3 Factors of Competition
- 3.6 Mergers, Acquisitions Activity

# 4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)

- 4.1 United States VS China: Therapeutic Radioligands Revenue Comparison (by Headquarter Location)
- 4.1.1 United States VS China: Therapeutic Radioligands Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
- 4.1.2 United States VS China: Therapeutic Radioligands Revenue Market Share Comparison (2018 & 2022 & 2029)
- 4.2 United States Based Companies VS China Based Companies: Therapeutic Radioligands Consumption Value Comparison
- 4.2.1 United States VS China: Therapeutic Radioligands Consumption Value Comparison (2018 & 2022 & 2029)
- 4.2.2 United States VS China: Therapeutic Radioligands Consumption Value Market Share Comparison (2018 & 2022 & 2029)
- 4.3 United States Based Therapeutic Radioligands Companies and Market Share, 2018-2023
- 4.3.1 United States Based Therapeutic Radioligands Companies, Headquarters (States, Country)
- 4.3.2 United States Based Companies Therapeutic Radioligands Revenue, (2018-2023)
- 4.4 China Based Companies Therapeutic Radioligands Revenue and Market Share, 2018-2023
  - 4.4.1 China Based Therapeutic Radioligands Companies, Company Headquarters



#### (Province, Country)

- 4.4.2 China Based Companies Therapeutic Radioligands Revenue, (2018-2023)
- 4.5 Rest of World Based Therapeutic Radioligands Companies and Market Share, 2018-2023
- 4.5.1 Rest of World Based Therapeutic Radioligands Companies, Headquarters (States, Country)
- 4.5.2 Rest of World Based Companies Therapeutic Radioligands Revenue, (2018-2023)

#### **5 MARKET ANALYSIS BY TYPE**

- 5.1 World Therapeutic Radioligands Market Size Overview by Type: 2018 VS 2022 VS 2029
- 5.2 Segment Introduction by Type
  - 5.2.1 Beta-emitting
  - 5.2.2 Targeted Alpha Therapy
- 5.3 Market Segment by Type
  - 5.3.1 World Therapeutic Radioligands Market Size by Type (2018-2023)
  - 5.3.2 World Therapeutic Radioligands Market Size by Type (2024-2029)
  - 5.3.3 World Therapeutic Radioligands Market Size Market Share by Type (2018-2029)

#### **6 MARKET ANALYSIS BY APPLICATION**

- 6.1 World Therapeutic Radioligands Market Size Overview by Application: 2018 VS 2022 VS 2029
- 6.2 Segment Introduction by Application
  - 6.2.1 Solid Tumor
  - 6.2.2 Non Hodgkin Lymphoma
- 6.3 Market Segment by Application
  - 6.3.1 World Therapeutic Radioligands Market Size by Application (2018-2023)
  - 6.3.2 World Therapeutic Radioligands Market Size by Application (2024-2029)
  - 6.3.3 World Therapeutic Radioligands Market Size by Application (2018-2029)

#### **7 COMPANY PROFILES**

- 7.1 Bayer
  - 7.1.1 Bayer Details
  - 7.1.2 Bayer Major Business
  - 7.1.3 Bayer Therapeutic Radioligands Product and Services



- 7.1.4 Bayer Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
  - 7.1.5 Bayer Recent Developments/Updates
  - 7.1.6 Bayer Competitive Strengths & Weaknesses
- 7.2 Novartis
  - 7.2.1 Novartis Details
  - 7.2.2 Novartis Major Business
  - 7.2.3 Novartis Therapeutic Radioligands Product and Services
- 7.2.4 Novartis Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
  - 7.2.5 Novartis Recent Developments/Updates
  - 7.2.6 Novartis Competitive Strengths & Weaknesses
- 7.3 Lantheus
  - 7.3.1 Lantheus Details
  - 7.3.2 Lantheus Major Business
  - 7.3.3 Lantheus Therapeutic Radioligands Product and Services
- 7.3.4 Lantheus Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
  - 7.3.5 Lantheus Recent Developments/Updates
  - 7.3.6 Lantheus Competitive Strengths & Weaknesses
- 7.4 Aurobindo Pharma
  - 7.4.1 Aurobindo Pharma Details
  - 7.4.2 Aurobindo Pharma Major Business
  - 7.4.3 Aurobindo Pharma Therapeutic Radioligands Product and Services
- 7.4.4 Aurobindo Pharma Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
  - 7.4.5 Aurobindo Pharma Recent Developments/Updates
  - 7.4.6 Aurobindo Pharma Competitive Strengths & Weaknesses
- 7.5 Mundipharma
  - 7.5.1 Mundipharma Details
  - 7.5.2 Mundipharma Major Business
  - 7.5.3 Mundipharma Therapeutic Radioligands Product and Services
- 7.5.4 Mundipharma Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
  - 7.5.5 Mundipharma Recent Developments/Updates
  - 7.5.6 Mundipharma Competitive Strengths & Weaknesses
- 7.6 China Isotope & Radiation
  - 7.6.1 China Isotope & Radiation Details
- 7.6.2 China Isotope & Radiation Major Business



- 7.6.3 China Isotope & Radiation Therapeutic Radioligands Product and Services
- 7.6.4 China Isotope & Radiation Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
- 7.6.5 China Isotope & Radiation Recent Developments/Updates
- 7.6.6 China Isotope & Radiation Competitive Strengths & Weaknesses
- 7.7 Curium Pharmaceuticals
  - 7.7.1 Curium Pharmaceuticals Details
  - 7.7.2 Curium Pharmaceuticals Major Business
  - 7.7.3 Curium Pharmaceuticals Therapeutic Radioligands Product and Services
- 7.7.4 Curium Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
  - 7.7.5 Curium Pharmaceuticals Recent Developments/Updates
  - 7.7.6 Curium Pharmaceuticals Competitive Strengths & Weaknesses
- 7.8 Gilead Sciences
  - 7.8.1 Gilead Sciences Details
  - 7.8.2 Gilead Sciences Major Business
  - 7.8.3 Gilead Sciences Therapeutic Radioligands Product and Services
- 7.8.4 Gilead Sciences Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
  - 7.8.5 Gilead Sciences Recent Developments/Updates
- 7.8.6 Gilead Sciences Competitive Strengths & Weaknesses
- 7.9 Clarity Pharmaceuticals
  - 7.9.1 Clarity Pharmaceuticals Details
  - 7.9.2 Clarity Pharmaceuticals Major Business
  - 7.9.3 Clarity Pharmaceuticals Therapeutic Radioligands Product and Services
- 7.9.4 Clarity Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
  - 7.9.5 Clarity Pharmaceuticals Recent Developments/Updates
  - 7.9.6 Clarity Pharmaceuticals Competitive Strengths & Weaknesses
- 7.10 Curasight
  - 7.10.1 Curasight Details
  - 7.10.2 Curasight Major Business
  - 7.10.3 Curasight Therapeutic Radioligands Product and Services
- 7.10.4 Curasight Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
- 7.10.5 Curasight Recent Developments/Updates
- 7.10.6 Curasight Competitive Strengths & Weaknesses
- 7.11 Nordic Nanovector
- 7.11.1 Nordic Nanovector Details



- 7.11.2 Nordic Nanovector Major Business
- 7.11.3 Nordic Nanovector Therapeutic Radioligands Product and Services
- 7.11.4 Nordic Nanovector Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
  - 7.11.5 Nordic Nanovector Recent Developments/Updates
  - 7.11.6 Nordic Nanovector Competitive Strengths & Weaknesses
- 7.12 Philogen
  - 7.12.1 Philogen Details
  - 7.12.2 Philogen Major Business
  - 7.12.3 Philogen Therapeutic Radioligands Product and Services
- 7.12.4 Philogen Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
  - 7.12.5 Philogen Recent Developments/Updates
  - 7.12.6 Philogen Competitive Strengths & Weaknesses
- 7.13 RadioMedix
  - 7.13.1 RadioMedix Details
  - 7.13.2 RadioMedix Major Business
  - 7.13.3 RadioMedix Therapeutic Radioligands Product and Services
- 7.13.4 RadioMedix Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
- 7.13.5 RadioMedix Recent Developments/Updates
- 7.13.6 RadioMedix Competitive Strengths & Weaknesses
- 7.14 Telix Pharmaceuticals
  - 7.14.1 Telix Pharmaceuticals Details
  - 7.14.2 Telix Pharmaceuticals Major Business
  - 7.14.3 Telix Pharmaceuticals Therapeutic Radioligands Product and Services
- 7.14.4 Telix Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
  - 7.14.5 Telix Pharmaceuticals Recent Developments/Updates
  - 7.14.6 Telix Pharmaceuticals Competitive Strengths & Weaknesses
- 7.15 Orano Med
  - 7.15.1 Orano Med Details
  - 7.15.2 Orano Med Major Business
  - 7.15.3 Orano Med Therapeutic Radioligands Product and Services
- 7.15.4 Orano Med Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
  - 7.15.5 Orano Med Recent Developments/Updates
  - 7.15.6 Orano Med Competitive Strengths & Weaknesses
- 7.16 Actinium Pharmaceuticals



- 7.16.1 Actinium Pharmaceuticals Details
- 7.16.2 Actinium Pharmaceuticals Major Business
- 7.16.3 Actinium Pharmaceuticals Therapeutic Radioligands Product and Services
- 7.16.4 Actinium Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
  - 7.16.5 Actinium Pharmaceuticals Recent Developments/Updates
- 7.16.6 Actinium Pharmaceuticals Competitive Strengths & Weaknesses
- 7.17 Y-mAbs Therapeutics
  - 7.17.1 Y-mAbs Therapeutics Details
  - 7.17.2 Y-mAbs Therapeutics Major Business
  - 7.17.3 Y-mAbs Therapeutics Therapeutic Radioligands Product and Services
- 7.17.4 Y-mAbs Therapeutics Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
  - 7.17.5 Y-mAbs Therapeutics Recent Developments/Updates
  - 7.17.6 Y-mAbs Therapeutics Competitive Strengths & Weaknesses
- 7.18 Fusion Pharmaceuticals
  - 7.18.1 Fusion Pharmaceuticals Details
  - 7.18.2 Fusion Pharmaceuticals Major Business
  - 7.18.3 Fusion Pharmaceuticals Therapeutic Radioligands Product and Services
- 7.18.4 Fusion Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
  - 7.18.5 Fusion Pharmaceuticals Recent Developments/Updates
  - 7.18.6 Fusion Pharmaceuticals Competitive Strengths & Weaknesses

#### **8 INDUSTRY CHAIN ANALYSIS**

- 8.1 Therapeutic Radioligands Industry Chain
- 8.2 Therapeutic Radioligands Upstream Analysis
- 8.3 Therapeutic Radioligands Midstream Analysis
- 8.4 Therapeutic Radioligands Downstream Analysis

#### 9 RESEARCH FINDINGS AND CONCLUSION

#### **10 APPENDIX**

- 10.1 Methodology
- 10.2 Research Process and Data Source
- 10.3 Disclaimer







# **List Of Tables**

#### LIST OF TABLES

- Table 1. World Therapeutic Radioligands Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
- Table 2. World Therapeutic Radioligands Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
- Table 3. World Therapeutic Radioligands Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
- Table 4. World Therapeutic Radioligands Revenue Market Share by Region (2018-2023), (by Headquarter Location)
- Table 5. World Therapeutic Radioligands Revenue Market Share by Region (2024-2029), (by Headquarter Location)
- Table 6. Major Market Trends
- Table 7. World Therapeutic Radioligands Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
- Table 8. World Therapeutic Radioligands Consumption Value by Region (2018-2023) & (USD Million)
- Table 9. World Therapeutic Radioligands Consumption Value Forecast by Region (2024-2029) & (USD Million)
- Table 10. World Therapeutic Radioligands Revenue by Player (2018-2023) & (USD Million)
- Table 11. Revenue Market Share of Key Therapeutic Radioligands Players in 2022
- Table 12. World Therapeutic Radioligands Industry Rank of Major Player, Based on Revenue in 2022
- Table 13. Global Therapeutic Radioligands Company Evaluation Quadrant
- Table 14. Head Office of Key Therapeutic Radioligands Player
- Table 15. Therapeutic Radioligands Market: Company Product Type Footprint
- Table 16. Therapeutic Radioligands Market: Company Product Application Footprint
- Table 17. Therapeutic Radioligands Mergers & Acquisitions Activity
- Table 18. United States VS China Therapeutic Radioligands Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
- Table 19. United States VS China Therapeutic Radioligands Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
- Table 20. United States Based Therapeutic Radioligands Companies, Headquarters (States, Country)
- Table 21. United States Based Companies Therapeutic Radioligands Revenue, (2018-2023) & (USD Million)



- Table 22. United States Based Companies Therapeutic Radioligands Revenue Market Share (2018-2023)
- Table 23. China Based Therapeutic Radioligands Companies, Headquarters (Province, Country)
- Table 24. China Based Companies Therapeutic Radioligands Revenue, (2018-2023) & (USD Million)
- Table 25. China Based Companies Therapeutic Radioligands Revenue Market Share (2018-2023)
- Table 26. Rest of World Based Therapeutic Radioligands Companies, Headquarters (States, Country)
- Table 27. Rest of World Based Companies Therapeutic Radioligands Revenue, (2018-2023) & (USD Million)
- Table 28. Rest of World Based Companies Therapeutic Radioligands Revenue Market Share (2018-2023)
- Table 29. World Therapeutic Radioligands Market Size by Type, (USD Million), 2018 & 2022 & 2029
- Table 30. World Therapeutic Radioligands Market Size by Type (2018-2023) & (USD Million)
- Table 31. World Therapeutic Radioligands Market Size by Type (2024-2029) & (USD Million)
- Table 32. World Therapeutic Radioligands Market Size by Application, (USD Million), 2018 & 2022 & 2029
- Table 33. World Therapeutic Radioligands Market Size by Application (2018-2023) & (USD Million)
- Table 34. World Therapeutic Radioligands Market Size by Application (2024-2029) & (USD Million)
- Table 35. Bayer Basic Information, Area Served and Competitors
- Table 36. Bayer Major Business
- Table 37. Bayer Therapeutic Radioligands Product and Services
- Table 38. Bayer Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 39. Bayer Recent Developments/Updates
- Table 40. Bayer Competitive Strengths & Weaknesses
- Table 41. Novartis Basic Information, Area Served and Competitors
- Table 42. Novartis Major Business
- Table 43. Novartis Therapeutic Radioligands Product and Services
- Table 44. Novartis Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 45. Novartis Recent Developments/Updates



- Table 46. Novartis Competitive Strengths & Weaknesses
- Table 47. Lantheus Basic Information, Area Served and Competitors
- Table 48. Lantheus Major Business
- Table 49. Lantheus Therapeutic Radioligands Product and Services
- Table 50. Lantheus Therapeutic Radioligands Revenue, Gross Margin and Market
- Share (2018-2023) & (USD Million)
- Table 51. Lantheus Recent Developments/Updates
- Table 52. Lantheus Competitive Strengths & Weaknesses
- Table 53. Aurobindo Pharma Basic Information, Area Served and Competitors
- Table 54. Aurobindo Pharma Major Business
- Table 55. Aurobindo Pharma Therapeutic Radioligands Product and Services
- Table 56. Aurobindo Pharma Therapeutic Radioligands Revenue, Gross Margin and
- Market Share (2018-2023) & (USD Million)
- Table 57. Aurobindo Pharma Recent Developments/Updates
- Table 58. Aurobindo Pharma Competitive Strengths & Weaknesses
- Table 59. Mundipharma Basic Information, Area Served and Competitors
- Table 60. Mundipharma Major Business
- Table 61. Mundipharma Therapeutic Radioligands Product and Services
- Table 62. Mundipharma Therapeutic Radioligands Revenue, Gross Margin and Market
- Share (2018-2023) & (USD Million)
- Table 63. Mundipharma Recent Developments/Updates
- Table 64. Mundipharma Competitive Strengths & Weaknesses
- Table 65. China Isotope & Radiation Basic Information, Area Served and Competitors
- Table 66. China Isotope & Radiation Major Business
- Table 67. China Isotope & Radiation Therapeutic Radioligands Product and Services
- Table 68. China Isotope & Radiation Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 69. China Isotope & Radiation Recent Developments/Updates
- Table 70. China Isotope & Radiation Competitive Strengths & Weaknesses
- Table 71. Curium Pharmaceuticals Basic Information, Area Served and Competitors
- Table 72. Curium Pharmaceuticals Major Business
- Table 73. Curium Pharmaceuticals Therapeutic Radioligands Product and Services
- Table 74. Curium Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 75. Curium Pharmaceuticals Recent Developments/Updates
- Table 76. Curium Pharmaceuticals Competitive Strengths & Weaknesses
- Table 77. Gilead Sciences Basic Information, Area Served and Competitors
- Table 78. Gilead Sciences Major Business
- Table 79. Gilead Sciences Therapeutic Radioligands Product and Services



- Table 80. Gilead Sciences Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 81. Gilead Sciences Recent Developments/Updates
- Table 82. Gilead Sciences Competitive Strengths & Weaknesses
- Table 83. Clarity Pharmaceuticals Basic Information, Area Served and Competitors
- Table 84. Clarity Pharmaceuticals Major Business
- Table 85. Clarity Pharmaceuticals Therapeutic Radioligands Product and Services
- Table 86. Clarity Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 87. Clarity Pharmaceuticals Recent Developments/Updates
- Table 88. Clarity Pharmaceuticals Competitive Strengths & Weaknesses
- Table 89. Curasight Basic Information, Area Served and Competitors
- Table 90. Curasight Major Business
- Table 91. Curasight Therapeutic Radioligands Product and Services
- Table 92. Curasight Therapeutic Radioligands Revenue, Gross Margin and Market
- Share (2018-2023) & (USD Million)
- Table 93. Curasight Recent Developments/Updates
- Table 94. Curasight Competitive Strengths & Weaknesses
- Table 95. Nordic Nanovector Basic Information, Area Served and Competitors
- Table 96. Nordic Nanovector Major Business
- Table 97. Nordic Nanovector Therapeutic Radioligands Product and Services
- Table 98. Nordic Nanovector Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Market Griare (2010 2020) & (OOD Million)
- Table 99. Nordic Nanovector Recent Developments/Updates
- Table 100. Nordic Nanovector Competitive Strengths & Weaknesses
- Table 101. Philogen Basic Information, Area Served and Competitors
- Table 102. Philogen Major Business
- Table 103. Philogen Therapeutic Radioligands Product and Services
- Table 104. Philogen Therapeutic Radioligands Revenue, Gross Margin and Market
- Share (2018-2023) & (USD Million)
- Table 105. Philogen Recent Developments/Updates
- Table 106. Philogen Competitive Strengths & Weaknesses
- Table 107. RadioMedix Basic Information, Area Served and Competitors
- Table 108. RadioMedix Major Business
- Table 109. RadioMedix Therapeutic Radioligands Product and Services
- Table 110. RadioMedix Therapeutic Radioligands Revenue, Gross Margin and Market
- Share (2018-2023) & (USD Million)
- Table 111. RadioMedix Recent Developments/Updates
- Table 112. RadioMedix Competitive Strengths & Weaknesses



- Table 113. Telix Pharmaceuticals Basic Information, Area Served and Competitors
- Table 114. Telix Pharmaceuticals Major Business
- Table 115. Telix Pharmaceuticals Therapeutic Radioligands Product and Services
- Table 116. Telix Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 117. Telix Pharmaceuticals Recent Developments/Updates
- Table 118. Telix Pharmaceuticals Competitive Strengths & Weaknesses
- Table 119. Orano Med Basic Information, Area Served and Competitors
- Table 120. Orano Med Major Business
- Table 121. Orano Med Therapeutic Radioligands Product and Services
- Table 122. Orano Med Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 123. Orano Med Recent Developments/Updates
- Table 124. Orano Med Competitive Strengths & Weaknesses
- Table 125. Actinium Pharmaceuticals Basic Information, Area Served and Competitors
- Table 126. Actinium Pharmaceuticals Major Business
- Table 127. Actinium Pharmaceuticals Therapeutic Radioligands Product and Services
- Table 128. Actinium Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 129. Actinium Pharmaceuticals Recent Developments/Updates
- Table 130. Actinium Pharmaceuticals Competitive Strengths & Weaknesses
- Table 131. Y-mAbs Therapeutics Basic Information, Area Served and Competitors
- Table 132. Y-mAbs Therapeutics Major Business
- Table 133. Y-mAbs Therapeutics Therapeutic Radioligands Product and Services
- Table 134. Y-mAbs Therapeutics Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 135. Y-mAbs Therapeutics Recent Developments/Updates
- Table 136. Fusion Pharmaceuticals Basic Information, Area Served and Competitors
- Table 137. Fusion Pharmaceuticals Major Business
- Table 138. Fusion Pharmaceuticals Therapeutic Radioligands Product and Services
- Table 139. Fusion Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 140. Global Key Players of Therapeutic Radioligands Upstream (Raw Materials)
- Table 141. Therapeutic Radioligands Typical Customers
- List of Figure
- Figure 1. Therapeutic Radioligands Picture
- Figure 2. World Therapeutic Radioligands Total Market Size: 2018 & 2022 & 2029, (USD Million)
- Figure 3. World Therapeutic Radioligands Total Market Size (2018-2029) & (USD



# Million)

Figure 4. World Therapeutic Radioligands Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Figure 5. World Therapeutic Radioligands Revenue Market Share by Region (2018-2029), (by Headquarter Location)

Figure 6. United States Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)

Figure 7. China Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)

Figure 8. Europe Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)

Figure 9. Japan Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)

Figure 10. South Korea Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)

Figure 11. ASEAN Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)

Figure 12. India Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)

Figure 13. Therapeutic Radioligands Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)

Figure 16. World Therapeutic Radioligands Consumption Value Market Share by Region (2018-2029)

Figure 17. United States Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)

Figure 18. China Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)

Figure 20. Japan Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)

Figure 23. India Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)



Figure 24. Producer Shipments of Therapeutic Radioligands by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for Therapeutic Radioligands Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Therapeutic Radioligands Markets in 2022

Figure 27. United States VS China: Therapeutic Radioligands Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Therapeutic Radioligands Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Therapeutic Radioligands Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Therapeutic Radioligands Market Size Market Share by Type in 2022

Figure 31. Beta-emitting

Figure 32. Targeted Alpha Therapy

Figure 33. World Therapeutic Radioligands Market Size Market Share by Type (2018-2029)

Figure 34. World Therapeutic Radioligands Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 35. World Therapeutic Radioligands Market Size Market Share by Application in 2022

Figure 36. Solid Tumor

Figure 37. Non Hodgkin Lymphoma

Figure 38. Therapeutic Radioligands Industrial Chain

Figure 39. Methodology

Figure 40. Research Process and Data Source



#### I would like to order

Product name: Global Therapeutic Radioligands Supply, Demand and Key Producers, 2023-2029

Product link: https://marketpublishers.com/r/G72246201812EN.html

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/G72246201812EN.html">https://marketpublishers.com/r/G72246201812EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970